SEC Form 4													
FC	ORM 4	STATES S	ECURITIES Washingt										
Section 16. F	ox if no longer subject 1 Form 4 or Form 5 Nay continue. See b).	∘ STAT	Filed pursuar	T CHANGES at to Section 16(a) of tion 30(h) of the Inv	of the Securitie	RSH	Estir	Number: nated average burd s per response:	3235-0287 len 0.5				
1. Name and Address of Reporting Person [*] <u>NEUPERT PETER M</u>				r Name and Ticker tive Biotechn				tionship of Reporti all applicable) Director	Reporting Person(s) to Issuer ble) 10% Owner				
(Last)	(First)	(Middle)	3. Date 12/13/	of Earliest Transac 2023	tion (Month/D	ay/Year)		Officer (give title below)	Other	(specify)			
C/O ADAPTIVE BIOTECHNOLOGIES CORPORATION			4. If Am	endment, Date of C	Driginal Filed (Month/Day/Year)	6. Individual or Joint/Group Filing (Check Applicable Line)						
	AKE AVENUE E	AST					X		e Reporting Pers re than One Rep				
(Street) SEATTLE WA 98109				Rule 10b5-1(c) Transaction Indication									
(City)	(State)	(Zip)				tion was made pursuant to a e 10b5-1(c). See Instruction		nstruction or written	plan that is intended	to satisfy			
		Table I - Non	-Derivative S	ecurities Acqu	uired, Disp	osed of, or Benefi	cially C	Dwned					
1. Title of Security (Instr. 3) 2. Trans Date (Month.				2A. Deemed Execution Date, if any	3. Transaction Code (Instr.	4. Securities Acquired (A) Disposed Of (D) (Instr. 3, 4		5. Amount of Securities Beneficially	6. Ownership Form: Direct (D) or Indirect	7. Nature of Indirect Beneficial			

1. Title of Security (Instr. 3)		Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	Code (Instr.					5. Amount of Securities Beneficially Owned Following Reported	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	v	Amount	(A) or (D)	Price	Transaction(s) (Instr. 3 and 4)		(1150. 4)
Common Stock		12/13/2023		М		100,000	Α	\$0.84	122,968	D	

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)															
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)	
				Code	v	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares		Transaction(s) (Instr. 4)		
Stock Option (right to buy)	\$0 .84	12/13/2023		М			100,000	(1)	12/23/2023	Common Stock	100,000	\$0	0	D	

Explanation of Responses:

1. The option vested with respect to 1/4 of the Shares under the grant on the year anniversary of December 23, 2013 and with respect to 1/48 of the Shares under the grant monthly thereafter.

<u>/s/ Peter M Neupert by Stacy L</u> <u>Taylor, Attorney-in-Fact</u>	<u>12/15/2023</u>
** Signature of Reporting Person	Date

Signature of Reporting Person

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

 * If the form is filed by more than one reporting person, see Instruction 4 (b)(v).

** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

SEC Form 4	
SEC FOIIII 4	